knowledge -WSS

knowledge

author：fashion 2025-09-30 00:09:29 - browse：58

A doctor climbs up a red ladder to a vine shaped like a DNA — biotech coverage from STAT — Adobe

Every morning, Victoria Rasberry gets up before 6 a.m., walks to the bedroom down the hall, and helps her 8-year-old daughter Addi slide into a set of contraptions that squeeze and suck out the thick mucus constantly threatening to choke her airways closed. She feeds Addi breakfast through a stomach tube and makes sure she has the right mix of the 28 different medications required to keep her free of pain, infections, and seizures. At some point, Rasberry’s five other children will wake up and start to get ready for school, including her youngest, Oliver. At 3-and-a-half years old, he’s a typical toddler — always running and giggling and getting into things. You would never know that he and Addi were born with the same mutation lurking in their DNA, a genetic glitch that causes a fatal neurodegenerative disease called metachromatic leukodystrophy, or MLD.

“When Addi was this age she had lost the ability to speak and was already using a ventilator to sleep at night,” Rasberry said. “It’s amazing to see how well Ollie is doing in comparison. And it’s all because of the gene therapy.”

Three years ago, when Ollie was just 6 months old, he and Victoria traveled from their home in Texas to Milan, to receive a gene therapy treatment that adds a healthy version of the defective gene into patients’ own stem cells. At the time, traveling abroad for the therapy, which is manufactured by Orchard Therapeutics and was approved in Europe in 2021, was the only option for families stricken by MLD. But soon it will be available in the U.S., too.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： After affirmative action ruling, medical educators look to 'holistic review'
Next article： Readout Newsletter: Beam, Prozac, "TechBio" and more

WSS

Redefining sustainability for the pharmaceutical industry

KalVista pill reduced swelling 'attacks' caused by genetic disease

Medicare isn't yet testing food as medicine

Why did Pfizer dish out millions for a Super Bowl ad?

Medicare Advantage isn’t working — for anyone

Redefining sustainability for the pharmaceutical industry

knowledge

knowledge

leisure time

After affirmative action ruling, medical educators look to 'holistic review'

Ohio train derailment: Experts on toxic chemical risks

Medical leaders decry Supreme Court decision on affirmative action

Childhood vaccination ad campaign launches in the U.K.

Drug repurposing or repositioning? The language matters

Readout Newsletter: Beam, Prozac, "TechBio" and more

As demand for Covid shots wanes, Moderna seeks its next success

What we’ve learned from the Aduhelm mess

Wildfire smoke exposes gaps in outdoor worker protections

For Medicare Advantage, Democrats want stronger protections around AI

hotspot

Using force crossed my mind when examining a defiant young patient

Industry veterans launch new biotech VC with $310M

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

Are embryos people? Reproductive medicine's future depends on the answer

CDC advisory group OKs chikungunya vaccine

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

hotspot

focus

hotspot

focus